Alzamend Neuro Ownership
| ALZN Stock | USD 0.69 0.02 2.99% |
Shares in Circulation | First Issued 2020-06-30 | Previous Quarter 3.5 M | Current Value 5.5 M | Avarage Shares Outstanding 4.3 M | Quarterly Volatility 2.3 M |
Alzamend |
Alzamend Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alzamend Neuro recorded a loss per share of 138.31. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 16th of July 2024. Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Alzamend Neuro operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Alzamend Neuro please contact Stephan Jackman at 844 722 6333 or go to https://www.alzamend.com.Besides selling stocks to institutional investors, Alzamend Neuro also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Alzamend Neuro's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Alzamend Neuro's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Alzamend Neuro Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Alzamend Neuro are currently held by insiders. Unlike Alzamend Neuro's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Alzamend Neuro's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Alzamend Neuro's insider trades
Alzamend Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alzamend Neuro is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alzamend Neuro backward and forwards among themselves. Alzamend Neuro's institutional investor refers to the entity that pools money to purchase Alzamend Neuro's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Activest Wealth Management | 2024-12-31 | 20.0 | Sbi Securities Co Ltd | 2024-12-31 | 18.0 | Advisor Group Holdings, Inc. | 2024-12-31 | 6.0 | Parallel Advisors, Llc | 2024-12-31 | 3.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 3.0 | Susquehanna International Group, Llp | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Rfg Advisory Group, Llc | 2024-09-30 | 0.0 | Corecap Advisors, Llc | 2024-12-31 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 33.5 K | Citadel Advisors Llc | 2024-12-31 | 30.6 K |
Alzamend Neuro Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alzamend Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alzamend Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alzamend Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alzamend Neuro Outstanding Bonds
Alzamend Neuro issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alzamend Neuro uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alzamend bonds can be classified according to their maturity, which is the date when Alzamend Neuro has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.